# Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)

> **NCT06134622** · PHASE3 · COMPLETED · sponsor: **The First Affiliated Hospital of University of Science and Technology of China** · enrollment: 832 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Intravenous thrombolysis plus tirofiban
- **DRUG:** Intravenous thrombolysis plus placebo

## Key facts

- **NCT ID:** NCT06134622
- **Lead sponsor:** The First Affiliated Hospital of University of Science and Technology of China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-14
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-12-30
- **Target enrollment:** 832 (ACTUAL)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06134622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06134622, "Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06134622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*